Analysis of ASCL1/NEUROD1/POU2F3/YAP1 Yields Novel Insights for the Diagnosis of Olfactory Neuroblastoma and Identifies Sinonasal Tuft Cell-like Carcinoma DOI

Christopher A. Febres‐Aldana,

M Elsayad,

Maelle Saliba

и другие.

Modern Pathology, Год журнала: 2024, Номер unknown, С. 100674 - 100674

Опубликована: Ноя. 1, 2024

Язык: Английский

Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer DOI Creative Commons
John B. Finlay, Abbie S. Ireland,

Sarah B. Hawgood

и другие.

Cancer Cell, Год журнала: 2024, Номер 42(6), С. 1086 - 1105.e13

Опубликована: Май 23, 2024

The olfactory epithelium undergoes neuronal regeneration from basal stem cells and is susceptible to neuroblastoma (ONB), a rare tumor of unclear origins. Employing alterations in Rb1/Trp53/Myc (RPM), we establish genetically engineered mouse model high-grade metastatic ONB exhibiting NEUROD1

Язык: Английский

Процитировано

5

Update on olfactory neuroblastoma DOI
Fernando López, Abbas Agaimy, Alessandro Franchi

и другие.

Virchows Archiv, Год журнала: 2024, Номер 484(4), С. 567 - 585

Опубликована: Фев. 22, 2024

Язык: Английский

Процитировано

4

Advancing Precision Medicine: The Role of Genetic Testing and Sequencing Technologies in Identifying Biological Markers for Rare Cancers DOI Creative Commons

Joviana Farhat,

Lara Alzyoud, Mohammad Alwahsh

и другие.

Cancer Medicine, Год журнала: 2025, Номер 14(8)

Опубликована: Апрель 1, 2025

ABSTRACT Background Genetic testing and sequencing technologies offer a comprehensive understanding of cancer genetics, providing rapid cost‐effective solutions. In particular, these advanced play an important role in assessing the complexities rare types affecting several systems including bone, endocrine, digestive, vascular, soft tissue. This review will explore how genetic have contributed to identification biomarkers across diagnostic, therapeutic, prognostic stages, thereby advancing PM. Methods A literature search was conducted PubMed (MEDLINE), EMBASE, Web Science using keywords related technologies, testing, cancer. There were no restrictions on language, methodology, age, or publication date. Both primary secondary research involving humans animals considered. Results practice, fluorescence situ hybridization, karyotype, microarrays other tests are mainly applied identify specific alterations mutations associated with progression. Sequencing such as next generation sequencing, polymerase chain reaction, whole genome exome enable analysis millions DNA fragments. These techniques assess structure, changes, gene expression profiles, epigenetic variations. Consequently, they help detect main intrinsic markers that crucial for personalizing diagnosis, treatment options, assessments, leading better patient prognosis. highlights why methods now considered tools research. However, still face multiple limitations, false positive results, limited precision, high costs. Conclusion significantly field by enabling key precision treatment, Despite existing their integration into clinical fields continues improve development personalized medicine strategies complex types.

Язык: Английский

Процитировано

0

Proceedings of the 2023 North American Society of Head and Neck Pathology Companion Meeting, New Orleans, LA, March 12, 2023: Navigating New Developments in High Grade Sinonasal Neuroendocrine and Neuroectodermal Neoplasms DOI
Lisa M. Rooper

Head and Neck Pathology, Год журнала: 2023, Номер 17(2), С. 299 - 312

Опубликована: Май 15, 2023

Язык: Английский

Процитировано

9

Spatiotemporal dynamics exhibited by horizontal basal cells reveal a pro-neurogenic pathway during injury-induced olfactory epithelium regeneration DOI Creative Commons
Jonathan D. Louie, Camila M. Barrios-Camacho,

Benjamin H. Bromberg

и другие.

iScience, Год журнала: 2024, Номер 27(5), С. 109600 - 109600

Опубликована: Март 27, 2024

Horizontal basal cells (HBCs) mediate olfactory epithelium (OE) regeneration following severe tissue injury. The dynamism of the post-injury environment is well illustrated by

Язык: Английский

Процитировано

2

Horizontal basal cells self-govern their neurogenic potential during injury-induced regeneration of the olfactory epithelium DOI Open Access
Jonathan D. Louie,

Benjamin H. Bromberg,

Matthew J. Zunitch

и другие.

Development, Год журнала: 2023, Номер 150(12)

Опубликована: Июнь 1, 2023

Horizontal basal cells (HBCs) residing within severely damaged olfactory epithelium (OE) mediate OE regeneration by differentiating into odorant-detecting sensory neurons (OSNs) and other tissue supporting non-neuronal cell types. Depending on both type integrity, the Notch signaling pathway can either positively or negatively regulate resident stem activity. Although Notch1 specifies HBC dormancy in uninjured OE, little is known about how HBCs are influenced following injury. Here, we show that depend a functional inversion of to appropriately regeneration. At 24 h post-injury, enhance Notch1-mediated signaling. Moreover, at 3 days post-injury when regenerating composed multiple layers, enrich ligand, Dll1. Notably, HBC-specific knockout increases quiescence impairs differentiation neuronal progenitors OSNs. Interestingly, complete Dll1 only decreases HBC-derived These data underscore context-dependent nature Furthermore, they reveal their own neurogenic potential after

Язык: Английский

Процитировано

5

Top IHC/ISH Hacks for and Molecular Surrogates of Poorly Differentiated Sinonasal Small Round Cell Tumors DOI Creative Commons
Diana Bell

Head and Neck Pathology, Год журнала: 2024, Номер 18(1)

Опубликована: Фев. 5, 2024

Abstract Background Poorly differentiated sinonasal small round cell tumors (SRCTs) are rare and heterogeneous, posing challenges in diagnosis treatment. Methods Recent advances molecular findings diagnostic refinement have promoted better understanding management of these tumors. Results The newly defined emerging entities demonstrate diverse morphologies, specific genomic signatures, clinical behavior from conventional counterparts. In this review SRCTs, emphasis is placed on the approach with employment a pertinent panel immunohistochemistry studies and/or tests, fine-tuned to latest WHO 5 classification sinonasal/paranasal personalized Conclusion Specifically, focuses epithelial neuroectodermal derivation.

Язык: Английский

Процитировано

1

Olfactory Neuroblastoma and Olfactory Carcinoma DOI
Michael W. Mikula, Lisa M. Rooper

Surgical pathology clinics, Год журнала: 2024, Номер 17(4), С. 637 - 652

Опубликована: Авг. 24, 2024

Язык: Английский

Процитировано

1

Olfactory neuroblastoma DOI Open Access
Somtochi Okafor, Saad Alshammari,

Vanessa Helou

и другие.

Mini-invasive Surgery, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 8, 2024

Originating from the olfactory neuroepithelium, neuroblastoma is a rare malignant tumor of nasal cavity that typically affects adults between ages 35 and 70. Clinical presentation predominantly consists nonspecific symptoms such as obstruction, drainage or epistaxis, thus illustrating need for thorough diagnostic workup. In addition to complete head neck examination, rigid endoscopy, biopsy imaging are necessary establish definitive diagnosis well plan treatment. Computed tomography (CT) magnetic resonance (MRI) primary modalities utilized assess bony invasion soft tissue involvement, respectively. Hyams grading system provides histologic assessment disease severity while various staging systems correlate anatomic location/progression. Treatment relies on both surgical intervention radiation. addition, ongoing research trials investigating therapeutic targets. Given risk recurrence, extended post-treatment surveillance remains necessary.

Язык: Английский

Процитировано

1

Sox2 and βIII-Tubulin as Biomarkers of Drug Resistance in Poorly Differentiated Sinonasal Carcinomas DOI Open Access
Luis R. Lopez, Laura Fernández, Virginia N. Cabal

и другие.

Journal of Personalized Medicine, Год журнала: 2023, Номер 13(10), С. 1504 - 1504

Опубликована: Окт. 18, 2023

Poorly differentiated sinonasal carcinomas (PDCs) are tumors that have a poor prognosis despite advances in classical treatment. Predictive and prognostic markers new personalized treatments could improve the oncological outcomes of patients. In this study, we analyzed SOX2 βIII-tubulin as biomarkers therapeutic impacts on these tumors. The cohort included 57 cases PDCs: 36 undifferentiated carcinoma (SNUC) cases, 13 olfactory neuroblastoma (ONB) 8 neuroendocrine (SNEC) cases. Clinical follow-up data were available for 26 Sox2 expression was detected using immunohistochemistry 6 (75%) SNEC 19 (53%) SNUC (46%) ONB absence staining correlated with higher rate recurrence (p = 0.015), especially distant recurrence. majority showed expression, strong positivity 85%, 75%, 64% SNEC, ONB, respectively. Tumors stronger demonstrated longer disease-free survival than those no or low 0.049). is common poorly has utility.

Язык: Английский

Процитировано

2